2022-2023 Influenza Season: Availability of Antiviral Medications (Updated 12/5/22)

- **Oseltamivir Phosphate Oral Suspension**
  - Product Available
  - Ajanta Pharma: 866-770-3029
  - Alvogen: 1-844-842-8672, Option 2
  - Amneal Pharmaceuticals: 1-877 835-5472, Option 1
  - Genentech: 1-800-551-2231
  - Lupin Pharmaceuticals: 1-866-587-4617
  - Teva Pharmaceuticals: 1-800-545-8800
  - Zydus Pharmaceuticals: 1-877-993-8779

- **Oseltamivir Phosphate 75 mg Capsules**
  - Product Available
  - Alembic Pharmaceuticals: 1-908-393-9604
  - Alvogen: 1-844-842-8672, Option 2
  - Amneal Pharmaceuticals: 1-877 835-5472, Option 1
  - Genentech: 1-800-551-2231
  - Hetero Labs: 1-866-495-1995
  - Lupin Pharmaceuticals: 1-866-587-4617
  - Macleods Pharmaceuticals: 1-888-677-0778
  - Novadoz Pharmaceuticals: 855-222-3227
  - Strides Pharma: 1-866-941-7875

- **Oseltamivir Phosphate 45 mg Capsules**
  - Product Unavailable. Product expected to be available by mid-December.
  - Amneal Pharmaceuticals: 1-877 835-5472, Option 1

- **Oseltamivir Phosphate 30 mg Capsules**
  - Product Available
  - Alembic Pharmaceuticals: 1-908-393-9604
  - Alvogen: 1-844-842-8672, Option 2
  - Genentech: 1-800-551-2231
  - Hetero Labs: 1-866-495-1995
  - Lupin Pharmaceuticals: 1-866-587-4617
  - Macleods Pharmaceuticals: 1-888-677-0778
  - Novadoz Pharmaceuticals: 855-222-3227
  - Strides Pharma: 1-866-941-7875
- **Unavailable. Additional product expected to be available by mid-December.**
  - Amneal Pharmaceuticals: 1-877 835-5472, Option 1

- **Relenza (zanamivir) Inhalation Powder**
  - Product Available
    - GlaxoSmithKline: 1-888-825-5249

- **Rapivab (peramivir) Injection**
  - Product Available
    - BioCryst Pharmaceuticals: 1-855-358-8966

- **Xofluza (baloxavir marboxil) 40 mg and 80 mg Tablets**
  - Product Available
    - Genentech: 1-800-551-2231

- **Additional Resources**
  - [CDC: Influenza (Flu)]
  - [CDC: Flu Treatment]
  - [FDA: Influenza (Flu) Antiviral Drugs and Related Information]

Although there currently is not a nationwide oseltamivir phosphate oral suspension shortage, we are aware there may be localized shortages where demand is especially high. Section 2.6 of the approved oseltamivir phosphate labeling (package insert) includes pharmacist instructions for oral suspension emergency compounding (final concentration 6 mg per mL) from 75 mg oseltamivir phosphate capsules when commercial oral suspension supplies are not readily available from wholesalers or the manufacturer.